Form 8-K Kymera Therapeutics, For: May 09
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- Wall Street ends lower, off record highs, as Treasury yields climb
- Applied Digital (APLD) Tops Q1 EPS by 26c, Beats on Revenue
Truist Securities 'Incrementally Positive' on Kymera Therapeutics (KYMR) Following Q1 Update
May 9, 2025 1:57 PM EDTTruist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $53.00 price target on Kymera Therapeutics (NASDAQ: KYMR) following Q1 results.
The analyst commented, "We are incrementally positive on KYMR following today's 1Q25 business update showcasing KT-579, an oral, selective degrader of... More



